AnteoTech (ADO) Q3 2025 TU earnings summary

Executive summary

• New CEO and board in place, with Glenda McLoughlin elected Chair and Merrill Gray as Interim MD/CEO, emphasizing transparency and strategic review.

• Strategic review underway to align activities with near-term market opportunities, including sales, marketing, and cost base.

• Focus on commercializing advanced battery materials and life sciences divisions, with expanded customer base and ongoing Mercedes-Benz Ultranode™ pouch cell testing.

• Life Sciences division pursued increased AnteoBind usage from Serum Institute of India and continued negotiations with Vidcare.

• Strategic partnerships, market engagement, and participation in major industry conferences are key priorities.

Financial highlights

• Closing cash balance at 31 March 2025 was $5.0 million, with no debt.

• Quarterly revenue from customers was $40,000; net cash outflows from operating activities were $2,148,000.

• Serum Institute of India has doubled its anticipated AnteoBind usage, indicating strong demand.

• Payments to related parties totaled $222,000 for directors' fees.

• Estimated 2.34 quarters of funding available based on current cash burn.

Outlook and guidance

• Strategic review to determine future direction, including cost, staffing, and investment, aiming to unlock immediate opportunities and align resources for growth.

• Focus remains on commercialising Ultranode™ technology and expanding partnerships in both battery and life sciences markets.

• Board and management committed to cost reductions and presenting high-value commercial propositions.

• Plans to deepen relationships and expand distribution in life sciences.

• Commercial deals are progressing slowly due to challenging market conditions.